Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.130
-0.070 (-3.18%)
At close: Aug 6, 2025, 4:00 PM
2.240
+0.110 (5.16%)
After-hours: Aug 6, 2025, 5:39 PM EDT
Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma.
Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Connect Biopharma Holdings Limited
| Country | United States |
| Founded | 2012 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Barry Quart |
Contact Details
Address: 3580 CARMEL MOUNTAIN ROAD, SUITE 200 San Diego, California 92130 United States | |
| Phone | 858 727 1040 |
| Website | connectbiopharm.com |
Stock Details
| Ticker Symbol | CNTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001835268 |
| CUSIP Number | 207523101 |
| ISIN Number | US2075231017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barry D. Quart Pharm.D. | Chief Executive Officer and Director |
| David L. Szekeres J.D. | President |
| Lisa Peraza CPA | Vice President of Finance |
| Jeff Cohn J.D. | General Counsel and Corporate Secretary |
| Sean T. Ristine | Vice President of Human Resources |
| Dr. Lei Sun Ph.D. | Vice President of Biologics and Head of CMC |
| Dr. Raul Collazo Ph.D. | Vice President and Global Head of Medical Affairs |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
| Kimberly J. Manhard | Executive Vice President and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 21, 2025 | SCHEDULE 13D/A | Filing |
| Jul 18, 2025 | F-6 POS | Post-effective amendments for immediately effective filing |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 9, 2025 | 8-K | Current Report |
| Jun 26, 2025 | EFFECT | Notice of Effectiveness |
| Jun 12, 2025 | UPLOAD | Filing |
| Jun 11, 2025 | 144 | Filing |
| Jun 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |